menu
    • menu
    [{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Duke University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Pharmacology\/Toxicology","graph2":"Preclinical","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RedHill Biopharma \/ Duke University School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"RedHill Biopharma \/ Duke University School of Medicine"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Pharmacology\/Toxicology","graph2":"Preclinical","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Incyte Corporation \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"NanoSurface Biomedical","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Funding","leadProduct":"Human Ipsc-Derived Cardiac Tissues","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Preclinical","graph3":"NanoSurface Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NanoSurface Biomedical \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"NanoSurface Biomedical \/ National Institutes of Health"},{"orgOrder":0,"company":"The Wistar Institute","sponsor":"Jubilant Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Preclinical","graph3":"The Wistar Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Wistar Institute \/ Jubilant Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"The Wistar Institute \/ Jubilant Therapeutics"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            RedHill Biopharma

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            RedHill Biopharma

                            Israel arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Opaganib

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Preclinical

                            Sponsor : Duke University School of Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            RedHill Collaborates with U.S. Academic Center on Opaganib for Phosgene Injury

                            Details : The collaboration is designed to test ABC294640 (opaganib), a first-in-class, orally administered SPHK2 selective inhibitor, as a potential medical countermeasure to treat phosgene inhalation injury.

                            Product Name : Yeliva

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 22, 2024

                            Lead Product(s) : Opaganib

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Preclinical

                            Sponsor : Duke University School of Medicine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Amryt Pharma

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Amryt Pharma

                            Ireland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Octreotide Acetate

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Amryt Receives Orphan Drug Designation from the FDA for Mycapssa (Oral Octreotide) for the Treatment of Carcin...

                            Details : Mycapssa® (octreotide capsules) is approved in the US for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. Mycapssa® is the first and only oral somatostatin analog approve...

                            Product Name : Mycapssa

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            July 14, 2022

                            Lead Product(s) : Octreotide Acetate

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            The Wistar Institute

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            The Wistar Institute

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Preclinical

                            Sponsor : Jubilant Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Jubilant Therapeutics Announces Research Collaboration with The Wistar Institute to Evaluate the Activity of N...

                            Details : Collaboration aims to evaluate the ability of Peptidyl Arginine Deiminase 4 (PAD4) inhibitors provided by Jubilant Therapeutics to block neutrophil extracellular trap (NET) formation in the context of COVID-19 related cytokine storms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 15, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Preclinical

                            Sponsor : Jubilant Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Incyte Corporation

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Incyte Corporation

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ruxolitinib Phosphate

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Preclinical

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Novartis, Incyte to test Jakavi for coronavirus-linked cytokine storm

                            Details : Novartis plans to initiate a Phase III clinical trial in collaboration with Incyte to evaluate the use of Jakavi for treatment of severe immune overreaction called cytokine storm in COVID-19.

                            Product Name : Jakavi

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 02, 2020

                            Lead Product(s) : Ruxolitinib Phosphate

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Preclinical

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            NanoSurface Biomedical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            NanoSurface Biomedical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Ipsc-Derived Cardiac Tissues

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $4.6 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            NanoSurface Biomedical Awarded $1.9M in Funding from NIH

                            Details : The SBIR funding will be used to develop NanoSurface’s innovative platform for modeling and assessing human cardiac function on-a-chip.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            March 03, 2020

                            Lead Product(s) : Human Ipsc-Derived Cardiac Tissues

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : $4.6 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth